adalimumab + methotrexate + rituximab

This is a combination therapy for rheumatoid arthritis (RA), typically used in patients with moderate to severe disease who have not responded adequately to conventional disease-modifying antirheumatic drugs (DMARDs) or biologic agents alone. Adalimumab is a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), methotrexate is an immunosuppressive DMARD that inhibits folate metabolism and modulates immune responses, and rituximab is a monoclonal antibody targeting CD20 on B cells. The combination aims to provide enhanced control of inflammation and joint damage by targeting multiple pathways involved in RA pathogenesis[2][3][5].

Other names

adalimumab, methotrexate, and rituximab combinationHumira plus methotrexate plus Rituxan